Keep in mind that the head of the FDA pediatrics is on NUGenerex’s advisory board. Generex, as we know, is planning for their results to be peer reviewed. That process takes awhile, but Joe said in the CC that investors will have an update soon. They probably have to be careful of how much info to reveal so they don’t lose the peer review. I’d guess an update next week or so as advised by Joe in the CC.